Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADTP 02
- Development stage
- Discontinued
- Lead developer
- Novartis
- Administration
- Unspecified Route
01
Overview
ADTP 02 is a drug candidate developed by Novartis, classified as a hepatoprotectant. Its precise mechanism of action remains undefined. It was undergoing Phase II clinical trials for the treatment of Non-alcoholic steatohepatitis (NASH) as part of a combination therapy in Switzerland. However, as of February 2023, Novartis's pipeline indicated no further development for this compound.
Beyond the preview
Go deeper on ADTP 02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADTP 02.